BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences:

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Wednesday, February 12 at 8:40-9:10 AM  
Location: Virtual

A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 90 days following the event.

Leerink Partners Global Healthcare Conference
Format: One-on-One meetings
Date and Time: Wednesday, March 12
Location: Miami Beach, Florida

37th Annual ROTH Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Monday, March 17, and Tuesday, March 18
Location: Dana Point, CA

About Galecto

Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, which Galecto acquired from Bridge Medicines. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com. 

For more information, contact:

Investors Contact:

Sandya von der Weid

This email address is being protected from spambots. You need JavaScript enabled to view it. 

+41 78 680 0538